PCVX SEC Filing News — Vaxcyte, Inc.

Latest SEC filings for Vaxcyte, Inc. (PCVX) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-09.

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conju…
Sector: Healthcare Industry: Biotechnology Market Cap: $10.4B
20
Total Filings
0
Bullish Classifications
5
Bearish Classifications
12
Insider Transactions
3
Material Events (8-K)
0
Periodic Reports
Rule-based classifications for PCVX currently lean bearish. Of the 20 filing records displayed, 5 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
PCVX Filing Activity Snapshot 2026-09-02 — 2026-10-09
Insider Transactions (Form 4)
0 buys vs 5 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$1.65M
Cowan Elvia (SVP, Finance & CAO) · 2026-10-07
19,000 shares · Form 4
Form 144 Notices
5
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 12 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 12 filings in this group are Form 4s for Vaxcyte, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 12 insider filings shown, the breakdown is 6 tax withholding, 5 open-market sale and 1 compensation award. 5 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Tax withholding ×6
Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.
Open-market sale ×5
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×1
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Form 4 Open-market sale Insider Selling 2026-10-07

PCVX insider Wassil Jim (EVP, Chief Scientific Ofc, COO) sold 18,000 shares (~$1.56M)

Wassil Jim, listed as EVP, Chief Scientific Ofc, COO at Vaxcyte, Inc., reported an open-market sale of 18,000 PCVX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 18,000 $5.35 $96.3K
S Open-market sale 18,000 $86.74 $1.56M
M Option exercise derivative · Stock Option (right to buy) 18,000 — —
Filing: Form 4 (Insider Transaction) Insider: Wassil Jim (EVP, Chief Scientific Ofc, COO) Shares: 18,000 Est. Value: $1.56M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-07

PCVX insider Cowan Elvia (SVP, Finance & CAO) sold 19,000 shares (~$1.65M)

Cowan Elvia, listed as SVP, Finance & CAO at Vaxcyte, Inc., reported an open-market sale of 19,000 PCVX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 19,000 $25.92 $492.5K
S Open-market sale 19,000 $86.74 $1.65M
M Option exercise derivative · Stock Option (right to buy) 19,000 — —
Filing: Form 4 (Insider Transaction) Insider: Cowan Elvia (SVP, Finance & CAO) Shares: 19,000 Est. Value: $1.65M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-02

PCVX insider Wassil Jim (EVP, Chief Scientific Ofc, COO) sold 2,250 shares (~$127.5K)

Wassil Jim, listed as EVP, Chief Scientific Ofc, COO at Vaxcyte, Inc., reported an open-market sale of 2,250 PCVX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 2,250 $5.35 $12.0K
S Open-market sale 2,155 $56.65 $122.1K
S Open-market sale 95 $57.09 $5.4K
M Option exercise derivative · Stock Option (right to buy) 2,250 — —
Filing: Form 4 (Insider Transaction) Insider: Wassil Jim (EVP, Chief Scientific Ofc, COO) Shares: 2,250 Est. Value: $127.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Tax withholding Tax / Compensation Filing 2026-09-09

PCVX insider Form 4 filed for equity award, exercise, or tax withholding

PICKERING GRANT (Director, CHIEF EXECUTIVE OFFICER) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 17,056 $60.36 $1.03M
Filing: Form 4 (Insider Transaction) Insider: PICKERING GRANT (Director, CHIEF EXECUTIVE OFFICER) Shares: 17,056
View on SEC EDGAR → Open Filing Document →
Form 4 Tax withholding Tax / Compensation Filing 2026-09-09

PCVX insider Form 4 filed for equity award, exercise, or tax withholding

GUGGENHIME ANDREW (PRESIDENT AND CFO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 7,155 $60.36 $431.9K
Filing: Form 4 (Insider Transaction) Insider: GUGGENHIME ANDREW (PRESIDENT AND CFO) Shares: 7,155
View on SEC EDGAR → Open Filing Document →
Form 4 Tax withholding Tax / Compensation Filing 2026-09-09

PCVX insider Form 4 filed for equity award, exercise, or tax withholding

Dhaliwal Harpreet S. (Chief Technical Ops Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 7,651 $60.36 $461.8K
Filing: Form 4 (Insider Transaction) Insider: Dhaliwal Harpreet S. (Chief Technical Ops Officer) Shares: 7,651
View on SEC EDGAR → Open Filing Document →
Form 4 Tax withholding Tax / Compensation Filing 2026-09-09

PCVX insider Form 4 filed for equity award, exercise, or tax withholding

Cowan Elvia (SVP, Finance & CAO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 1,327 $60.36 $80.1K
Filing: Form 4 (Insider Transaction) Insider: Cowan Elvia (SVP, Finance & CAO) Shares: 1,327
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-09

PCVX insider Wassil Jim (EVP, Chief Scientific Ofc, COO) sold 2,715 shares (~$163.9K)

Wassil Jim, listed as EVP, Chief Scientific Ofc, COO at Vaxcyte, Inc., reported an open-market sale of 2,715 PCVX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,381 $61.16 $84.5K
F Tax withholding on vested shares 5,459 $60.36 $329.5K
S Open-market sale 1,334 $59.52 $79.4K
Filing: Form 4 (Insider Transaction) Insider: Wassil Jim (EVP, Chief Scientific Ofc, COO) Shares: 2,715 Est. Value: $163.9K
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-09-09

PCVX insider Form 4 filed for equity award, exercise, or tax withholding

Jodar Luis (Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 52,632 — —
A Compensation award derivative · Stock Option (right to buy) 88,254 — —
Filing: Form 4 (Insider Transaction) Insider: Jodar Luis (Chief Medical Officer) Shares: 52,632
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-02

PCVX insider Wassil Jim (CHIEF OPERATING OFFICER) sold 3,477 shares (~$212.4K)

Wassil Jim, listed as CHIEF OPERATING OFFICER at Vaxcyte, Inc., reported an open-market sale of 3,477 PCVX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 1,273 $60.74 $77.3K
M Option exercise 2,250 $5.35 $12.0K
S Open-market sale 1,537 $60.89 $93.6K
S Open-market sale 713 $61.48 $43.8K
S Open-market sale 924 $60.95 $56.3K
S Open-market sale 303 $61.42 $18.6K
F Tax withholding on vested shares 1,432 $61.58 $88.2K
M Option exercise derivative · Stock Option (right to buy) 2,250 — —
Filing: Form 4 (Insider Transaction) Insider: Wassil Jim (CHIEF OPERATING OFFICER) Shares: 3,477 Est. Value: $212.4K
View on SEC EDGAR → Open Filing Document →
Form 4 Tax withholding Tax / Compensation Filing 2026-09-02

PCVX insider Form 4 filed for equity award, exercise, or tax withholding

PICKERING GRANT (Director, CHIEF EXECUTIVE OFFICER) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 2,862 $60.74 $173.8K
F Tax withholding on vested shares 3,427 $61.58 $211.0K
Filing: Form 4 (Insider Transaction) Insider: PICKERING GRANT (Director, CHIEF EXECUTIVE OFFICER) Shares: 6,289
View on SEC EDGAR → Open Filing Document →
Form 4 Tax withholding Tax / Compensation Filing 2026-09-02

PCVX insider Form 4 filed for equity award, exercise, or tax withholding

GUGGENHIME ANDREW (PRESIDENT AND CFO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 1,273 $60.74 $77.3K
F Tax withholding on vested shares 1,432 $61.58 $88.2K
Filing: Form 4 (Insider Transaction) Insider: GUGGENHIME ANDREW (PRESIDENT AND CFO) Shares: 2,705
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 5 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Vaxcyte, Inc. has 5 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-10-05

PCVX Form 144 filed for proposed insider sale by Cowan Elvia (19,000 shares) ~$1.65M

Cowan Elvia filed a Form 144 with the SEC indicating intent to sell PCVX (Vaxcyte, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Cowan Elvia Shares: 19,000 Est. Value: $1.65M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-10-05

PCVX Form 144 filed for proposed insider sale by Wassil Jim (18,000 shares) ~$1.56M

Wassil Jim filed a Form 144 with the SEC indicating intent to sell PCVX (Vaxcyte, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Wassil Jim Shares: 18,000 Est. Value: $1.56M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-10-01

PCVX Form 144 filed for proposed insider sale by Wassil Jim (2,250 shares) ~$127.6K

Wassil Jim filed a Form 144 with the SEC indicating intent to sell PCVX (Vaxcyte, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Wassil Jim Shares: 2,250 Est. Value: $127.6K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-09

PCVX Form 144 filed for proposed insider sale by Wassil Jim (1,334 shares) ~$80.0K

Wassil Jim filed a Form 144 with the SEC indicating intent to sell PCVX (Vaxcyte, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Wassil Jim Shares: 1,334 Est. Value: $80.0K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-04

PCVX Form 144 filed for proposed insider sale by Wassil Jim (1,381 shares) ~$82.5K

Wassil Jim filed a Form 144 with the SEC indicating intent to sell PCVX (Vaxcyte, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Wassil Jim Shares: 1,381 Est. Value: $82.5K
View on SEC EDGAR → Open Filing Document →
Material Events 3 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 3 in this period for Vaxcyte, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-09

PCVX filed 8-K — material company event

Vaxcyte, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-10-05

PCVX filed 8-K — material company event

Vaxcyte, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-09-03

PCVX filed 8-K — material company event

Vaxcyte, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →

How we classify Vaxcyte, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on PCVX. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — PCVX SEC Filings

More Tools for PCVX

PCVX Full Stock Analysis PCVX Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper PCVX analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the PCVX stock analysis page.

PCVX Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer